These cheap antiparasitic drugs disrupt several processes cancer cells rely on in laboratory and animal studies, and are widely available and generally well tolerated short-term. Human evidence stays weak — cell studies, patient stories, and one uncontrolled survey, with no completed randomized trials. Main concerns are liver strain, blood-count effects, and delaying proven treatment. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT / AST | ~10–26 U/L | Detect drug-induced liver injury early |
| Bilirubin | ~0.3–1.0 mg/dL | Flags more significant liver stress |
| Neutrophils | ~1.8–6.0 ×10⁹/L | Detect bone-marrow suppression before infection risk |
| Platelets | ~175–250 ×10⁹/L | Screen for marrow suppression and bleeding risk |
| Albumin | ~4.0–5.0 g/dL | Marker of nutritional and liver status and overall reserve |
| C-reactive protein | <1.0 mg/L | Track systemic inflammation and tumor-related activity |
| Lactate dehydrogenase (LDH) | ~140–200 U/L | General marker of tumor burden and cell turnover |
Cadence: Liver enzymes and complete blood count at baseline, ~4 weeks, then every 4–8 weeks during use (more often with chemotherapy); tumor imaging roughly every 3 months